Researchers at the Cross Cancer Institute in Edmonton, Alberta are presently recruiting patients for a new trial to determine if "epirubicin dosing based on people's genetic profile" is a better method to calculate chemotherapy dosage versus the traditional means of determining dosage according to a patient's height and weight.
Led by Dr. John Mackey and Dr. Michael Sawyer, female patients with histologically confirmed non-metastatic invasive breast cancer "scheduled to receive at least three cycles of FEC100 in theh adjuvant or neoadjuvant setting" are elligible for participation in this trial.
Click here for further information.
No comments:
Post a Comment